A Phase II, Open-Labeled, Multi-Centre, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)
This is an open-label, randomized, multi-centre, comparator Phase II trial looking at the
addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with
progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of
initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68
weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of
Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered
every two weeks IV for the initial 24 weeks. Randomization will take place at the time of
registration taking into account NF1 and BRAF-KIAA1549-fusion status.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society